Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.42 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21437308 | 1.00 | SMN1; SMN2 (0.65) | SMN1; SMN2KEAP1NFE2L2MAPTKMT2A | |
| SCHEMBL21449529 | 0.86 | KEAP1 (0.51) | SMN1; SMN2KEAP1NFE2L2MAPTKMT2A | |
| SCHEMBL22901135 | 0.86 | KEAP1 (0.51) | SMN1; SMN2KEAP1NFE2L2MAPTKMT2A | |
| SCHEMBL22901097 | 0.86 | KEAP1 (0.51) | SMN1; SMN2KEAP1NFE2L2MAPTKMT2A | |
| SCHEMBL21437310 | 0.81 | KEAP1 (0.54) | SMN1; SMN2KEAP1NFE2L2KMT2AHSD17B10 | |
| SCHEMBL21437271 | 0.81 | KEAP1 (0.54) | SMN1; SMN2KEAP1NFE2L2KMT2AHSD17B10 | |
| SCHEMBL21437460 | 0.80 | GAA (0.44) | SMN1; SMN2KEAP1NFE2L2MAPTKMT2A | |
| SCHEMBL11055247 | 0.79 | SMN1; SMN2 (1.00) | SMN1; SMN2MAPTKMT2AHSD17B10ALDH1A1 | |
| SCHEMBL708635 | 0.77 | SMN1; SMN2 (0.63) | SMN1; SMN2KEAP1NFE2L2MAPTKMT2A | |
| SCHEMBL708634 | 0.77 | SMN1; SMN2 (0.63) | SMN1; SMN2KEAP1NFE2L2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773536-A1 | 1,4-SUBSTITUTED ISOQUINOLINE INHIBITORS OF KEAP1/NRF2 PROTEIN-PROTEIN INTERACTION | The Board of Trustees of the University of Illinois (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210017135-A1 | 1,4-SUBSTITUTED ISOQUINOLINE INHIBITORS OF KEAP1/NRF2 PROTEIN-PROTEIN INTERACTION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2021-01-21 | — | — | US | disclosed |
| WO-2019195348-A1 | 1,4-SUBSTITUTED ISOQUINOLINE INHIBITORS OF KEAP1/NRF2 PROTEIN-PROTEIN INTERACTION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017135-A1 | 1,4-SUBSTITUTED ISOQUINOLINE INHIBITORS OF KEAP1/NRF2 PROTEIN-PROTEIN INTERACTION | KEAP1, NFE2L2, NFE2 | SMN1; SMN2 1670/4885KEAP1 1/4885NFE2L2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.